Source - RNS
RNS Number : 3321R
Kazera Global PLC
14 June 2018
 

14 June 2018

Kazera Global

Investee Company Operational Update

 

Kazera Global plc ("Kazera Global" or "the Company") the AIM quoted investment company who, through its stake in African Tantalum (Pty) Limited ("Aftan"), has an interest in the Namibia Tantalite Investment Mine ("NTI" or the "Mine") in Namibia, provides the following operational update.

 

Kazera Global confirms that it has commissioned the MSA Group ("MSA"), a leading provider of exploration, mineral resources and reserve estimation, to carry out the targeted exploration programme designed to test and define total mineralisation across the NTI licence area, which forms the strategic focus of Aftan outlined in the announcement of 17 May 2018.

 

The new drilling programme will predominantly focus on tantalum and lithium resources across the licence and, as the exploration programme across the property develops, the Company expects to provide updates on JORC results as each specific ore body is drilled, tested and analysed. MSA has mobilised to site to begin the programme.

 

 

**ENDS**

Kazera Global plc (c/o Camarco)

Tel: +44 (0)203 757 4980

Larry Johnson (CEO)

 

finnCap (Nominated Adviser and Joint broker)

Christopher Raggett / Scott Mathieson / Anthony Adams (corporate finance)

 

Tel: +44 (0)207 220 0500

 

Shore Capital (Joint broker)

Mark Percy / Toby Gibbs (corporate finance)

Jerry Keen (corporate broking)

Tel: +44 (0)207 408 4090

Camarco (PR)

Gordon Poole / James Crothers / Monique Perks

Tel: +44 (0)203 757 4980

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
UPDFKNDQABKDCAD